JP7536654B2 - Ｌｉｆに対する抗体及びそれらの投与形態 - Google Patents

Ｌｉｆに対する抗体及びそれらの投与形態 Download PDF

Info

Publication number
JP7536654B2
JP7536654B2 JP2020563980A JP2020563980A JP7536654B2 JP 7536654 B2 JP7536654 B2 JP 7536654B2 JP 2020563980 A JP2020563980 A JP 2020563980A JP 2020563980 A JP2020563980 A JP 2020563980A JP 7536654 B2 JP7536654 B2 JP 7536654B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020563980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523906A (ja
JP2021523906A5 (enExample
Inventor
ジョアン・セオアネ・スアレス
ジュディット・アニド・フォルゲイラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Original Assignee
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institut d'Investigació Oncològica Vall-Hebron, MedImmune Ltd filed Critical Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
Publication of JP2021523906A publication Critical patent/JP2021523906A/ja
Publication of JP2021523906A5 publication Critical patent/JP2021523906A5/ja
Priority to JP2024130558A priority Critical patent/JP2024160301A/ja
Application granted granted Critical
Publication of JP7536654B2 publication Critical patent/JP7536654B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020563980A 2018-05-14 2019-05-13 Ｌｉｆに対する抗体及びそれらの投与形態 Active JP7536654B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024130558A JP2024160301A (ja) 2018-05-14 2024-08-07 Ｌｉｆに対する抗体及びそれらの投与形態

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18382327.7 2018-05-14
EP18382327 2018-05-14
EP18382359 2018-05-25
EP18382359.0 2018-05-25
EP19382208.7 2019-03-26
EP19382208 2019-03-26
EP19382331.7 2019-05-03
EP19382331 2019-05-03
PCT/IB2019/000541 WO2019220204A2 (en) 2018-05-14 2019-05-13 Antibodies against lif and dosage forms thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024130558A Division JP2024160301A (ja) 2018-05-14 2024-08-07 Ｌｉｆに対する抗体及びそれらの投与形態

Publications (3)

Publication Number Publication Date
JP2021523906A JP2021523906A (ja) 2021-09-09
JP2021523906A5 JP2021523906A5 (enExample) 2022-05-20
JP7536654B2 true JP7536654B2 (ja) 2024-08-20

Family

ID=67902550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563980A Active JP7536654B2 (ja) 2018-05-14 2019-05-13 Ｌｉｆに対する抗体及びそれらの投与形態
JP2024130558A Pending JP2024160301A (ja) 2018-05-14 2024-08-07 Ｌｉｆに対する抗体及びそれらの投与形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024130558A Pending JP2024160301A (ja) 2018-05-14 2024-08-07 Ｌｉｆに対する抗体及びそれらの投与形態

Country Status (10)

Country Link
US (1) US20220064279A1 (enExample)
EP (1) EP3794031A2 (enExample)
JP (2) JP7536654B2 (enExample)
KR (1) KR20210008514A (enExample)
CN (1) CN112638941A (enExample)
AU (1) AU2019269131B2 (enExample)
CA (1) CA3099406A1 (enExample)
MA (1) MA52021A (enExample)
SG (1) SG11202011170YA (enExample)
WO (1) WO2019220204A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7379390B2 (ja) * 2018-06-18 2023-11-14 メドイミューン・リミテッド 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2021110873A1 (en) * 2019-12-04 2021-06-10 Medimmune Limited Antibodies against lif and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522756A (ja) 2009-04-03 2012-09-27 フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
WO2017089614A1 (en) 2015-11-27 2017-06-01 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Agents for the treatment of diseases associated with undesired cell proliferation
JP2017527582A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
JP2017534617A (ja) 2014-10-21 2017-11-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患の処置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
CN112585164A (zh) * 2018-04-12 2021-03-30 免疫医疗有限公司 用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522756A (ja) 2009-04-03 2012-09-27 フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
JP2017527582A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
JP2017534617A (ja) 2014-10-21 2017-11-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患の処置
WO2017089614A1 (en) 2015-11-27 2017-06-01 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Agents for the treatment of diseases associated with undesired cell proliferation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Immunological Methods，1992年，Vol.156，pp.9-17
Oncotarget，2014年，Vol.5, No.3，pp.788-801

Also Published As

Publication number Publication date
AU2019269131A1 (en) 2021-01-07
US20220064279A1 (en) 2022-03-03
JP2021523906A (ja) 2021-09-09
SG11202011170YA (en) 2020-12-30
WO2019220204A3 (en) 2019-12-26
JP2024160301A (ja) 2024-11-13
MA52021A (fr) 2021-03-24
WO2019220204A2 (en) 2019-11-21
CA3099406A1 (en) 2019-11-21
KR20210008514A (ko) 2021-01-22
AU2019269131B2 (en) 2024-02-22
CN112638941A (zh) 2021-04-09
EP3794031A2 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
US10583191B2 (en) Antibodies against LIF and uses thereof
JP7459173B2 (ja) Ｌｉｆに対する抗体及びその使用
JP2024160301A (ja) Ｌｉｆに対する抗体及びそれらの投与形態
JP7423598B2 (ja) がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
JP7603772B2 (ja) 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
EA044934B1 (ru) Антитела к lif и лекарственные формы на их основе
HK40042216A (en) Antibodies against lif and dosage forms thereof
HK40040276B (en) Antibodies against lif and uses thereof
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo
EA045781B1 (ru) Антитела к lif и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240807

R150 Certificate of patent or registration of utility model

Ref document number: 7536654

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150